Omada Health (NASDAQ:OMDA) CEO Sells $587,094.48 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 25,886 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $22.68, for a total transaction of $587,094.48. Following the completion of the transaction, the chief executive officer owned 411,861 shares in the company, valued at approximately $9,341,007.48. This trade represents a 5.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Omada Health Stock Up 2.1%

Shares of Omada Health stock traded up $0.46 during trading on Monday, reaching $22.85. The company’s stock had a trading volume of 727,962 shares, compared to its average volume of 1,212,556. The company has a market cap of $1.36 billion and a price-to-earnings ratio of -84.63. Omada Health, Inc. has a 52-week low of $10.28 and a 52-week high of $26.92. The firm’s 50-day moving average is $17.32 and its two-hundred day moving average is $15.09.

Omada Health (NASDAQ:OMDA) last announced its earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The company had revenue of $78.05 million during the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. On average, equities research analysts anticipate that Omada Health, Inc. will post -0.01 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of OMDA. Geode Capital Management LLC purchased a new stake in shares of Omada Health during the second quarter valued at $637,000. Walleye Capital LLC bought a new stake in shares of Omada Health in the second quarter worth approximately $458,000. Ilex Capital Partners UK LLP purchased a new position in shares of Omada Health during the second quarter valued at approximately $201,000. Soros Fund Management LLC bought a new position in Omada Health during the second quarter valued at approximately $640,000. Finally, Raymond James Financial Inc. purchased a new stake in Omada Health in the second quarter worth approximately $32,000.

Wall Street Analyst Weigh In

OMDA has been the subject of a number of analyst reports. Weiss Ratings raised Omada Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. JPMorgan Chase & Co. cut their target price on Omada Health from $32.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, March 12th. Canaccord Genuity Group set a $24.00 price target on Omada Health in a research report on Friday, May 8th. Citigroup reiterated an “outperform” rating on shares of Omada Health in a research note on Friday, May 8th. Finally, Barclays increased their price objective on shares of Omada Health from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Omada Health currently has an average rating of “Moderate Buy” and a consensus price target of $22.91.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.